The EZ-riding NK/ T-cell lymphoma

Abstract

In this issue of Blood, Li and colleagues eloquently describe the oncogenic interplay between the maternal embryonic leucine zipper kinase (MELK) and the enhancer of zeste homolog 2 (EZH2) in extranodal natural killer/T-cell lymphoma (NKTL) through the phosphorylation-dependent loss of ubiquitination. Their work significantly enhances our understanding of the pathophysiology of extranodal NKTL and provides additional evidence for targeting this enzymatic pathway in mature NK/T-cell malignancies.